Showing results (91-100 of 205) with videos related to
Sort By:
Pageof 21
Cancer Chemotherapy and Pharmacology|January 2, 2021
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patientsNastja Lunar, Marie-Christine Etienne-Grimaldi, Pauline Macaire, et al.Cancer|November 18, 2022
Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancerJoris Mallard, Elyse Hucteau, Roland Schott, et al.JAMA Oncology|April 19, 2019
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical TrialChristian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, et al.European Journal of Cancer (Oxford, England : 1990)|July 12, 2015
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III studyXavier Pivot, Thomas Suter, Jean Marc Nabholtz, et al.The Oncologist|July 19, 2018
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III StudyKyung Hae Jung, Beyhan Ataseven, Mark Verrill, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineEdith A Perez, Guillermo Lerzo, Xavier Pivot, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 26, 2013
First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysisVirginie Nerich, Jennifer Chelly, Philippe Montcuquet, et al.Breast (Edinburgh, Scotland)|August 21, 2013
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancerGiuseppe Curigliano, Xavier Pivot, Javer Cortés, et al.Breast (Edinburgh, Scotland)|December 26, 2013
Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutionsFrederic Fiteni, Cristian Villanueva, Fernando Bazan, et al.Oral Oncology|March 4, 2005
Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancerXavier Pivot, Nicolas Magné, Emmanuel Guardiola, et al.Pageof 21